

SUVEN Life Sciences

Communication to investors June 2013

13-Aug-13

2013-14 Q1 results

Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW Quarter 1 – June 2013

•	Growth in revenue	57.38%
	Crowth in DAT	070 060/

- Growth in PAT 273.86%
- Growth in EBIDTA
- Growth in Pre-R&D EBIDTA
- R&D cost on revenue


57.38% 273.86% 233.20% 139.41% 7.10%

MAJOR PROFITABILITY RATIOS

	Q1 June 13	Q1 June 12
PAT to Income	26.62%	11.21%
EBIDTA to Income	41.30%	19.51%
Cash Flow to Income	28.50%	13.79%
Pre-R&D EBITDA to Income	48.40%	31.82%




INCOME COMPARISON






PROFIT COMPARISON




13-Aug-13






EBIDTA COMPARISON






R & D – EXPENDITURE






PRE-R&D EBIDTA





PRE-R&D CASHFLOW





Updates for the quarter

- During the quarter there were major qualitative achievements with the grant of 16 (sixteen) product patents to Suven's drug discovery pipeline which consists of 13 molecules out of which twelve (12) molecules currently in pre-clinical stage of development in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
- Suven has a patent profile of 18 inventions, 569 product patents and 36 process patents.